Abstract
Introduction
Left ventricular hypertrophy (LVH) is a common complication of hypertension, and is recognised as a risk factor for the development of congestive heart failure, myocardial infarction, and cardiac arrhythmias. 1, 2 In response to different humoral and mechanical stimuli, the myocardium adapts to increased workload through the hypertrophy of individual muscle cells. 3, 4 Myocardial hypertrophy is characterised by an increase in cell size in the absence of cell division and is associated with both adaptive and adverse changes in gene expression. 5 The molecular pathways that participate in the hypertrophic process are largely unknown. However, some foetal and growth genes have been found to be classically associated with the genetic programme of hypertrophy. 6, 7 Besides haemodynamic factors, there is increasing evidence for a crucial role for the renin-angiotensin system (RAS) in the pathophysiology of LVH. 8 Angiotensin II (Ang II) has been suggested to promote cell growth by activation of the Ang II subtype 1 (AT1) receptor. 9 Moreover, recent clinical and experimental studies have demonstrated that pharmacological agents, such as angiotensinconverting enzyme (ACE) inhibitors, can reduce LVH independently of a reduction in blood pressure. 10, 11 Genetically modified rats provide a simple and accessible model to investigate the genetic mechanisms of hypertension. The transgenic hypertensive TGR(mRen2)27 rat was generated by inserting the mouse salivary gland renin gene (mRen2) into the genome of the normotensive SpragueDawley Hanover rat. 12 The gene product is capable of converting rat renin substrate and thus generates angiotensin I (Ang I) from endogenous angiotensinogen. TGR(mRen2)27 rats develop severe hypertension, cardiovascular remodelling and overexpress the transgene in a number of tissues, including the central nervous system, the adrenal gland, the kidney, and the heart. [13] [14] [15] These transgenic rats have decreased endogenous renal renin expression but have their adrenal renin, plasma pronenin levels and tissue Ang II content markedly increased. 12, 14 However, conflicting results have been reported on plasma renin activity and Ang II levels. [12] [13] [14] This monogenic model offers the possibility of studying the mechanisms by which a single gene contributes to the pathogenesis of hypertension and cardiovascular disease.
The aim of this study was to identify new genes involved in the LVH of renin-dependent hypertension. Macroarray gene expression analysis was performed on the left ventricles of TGR(mRen2)27 compared to their littermate controls. Macroarray results of this study show that
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sperm membrane protein (YWK-II) is overexpressed in the left ventricle of these animals.YWK-II is identical to amyloid precursor like protein 2 (APLP2). 16 APLP2 is a member of the amyloid precursor protein (APP) family (APP, APLP1 and APLP2) and APP has been reported to be implicated in the generation of the β-A4 peptide in Alzheimer's disease (AD). 17 Consequently, APLP2 and APP gene expression were further determined by RT-PCR in the left ventricle of TGR(mRen2)27, spontaneously hypertensive rats (SHR) and the genetically Lyon hypertensive rats (LH) to determine if these genes were associated with hypertension or LVH.
Methods

Animals
Transgenic heterozygous 8, 12 and 20-week-old TGR(mRen2)27 male rats (TG+/-) were obtained from our own colony (n=5 per age). The transgene is integrated in SD Hanover rats. Non-transgenic littermates (TG-/-) were used as controls (n=5 per age). Male 12-week-old SHR (n=5) and Wistar-Kyoto (WKY) rats (n=5) were obtained from Charles River laboratories (IFFA-CREDO, L'Arbresle, France). Male 12-week-old LH rats (n=5) and their control strain, the Lyon low blood pressure (LL) rats (n=5) were obtained from the breeding colony of CNRS FRE 2678, Lyon, France.
Systolic blood pressure measurements and tissue preparation
Systolic blood pressure (SBP) was measured by tail-cuff plethysmography (IITC, Inc., Woodland Hills, CA, USA). The body weight (BW) was checked and animals were sacrificed after intraperitoneal anaesthesia with pentobarbital. The heart was rapidly removed, and the weights of heart and each ventricle were determined. Cardiac tissue was frozen in liquid nitrogen, and stored at -80°C.
Total RNA isolation
Total RNA was extracted from left ventricular tissue using Trizol Reagent (Invitrogen, Carlsbad, CA, USA) and treated with DNase (Deoxyribonuclease I, Amplification Grade), according to the manufacturer's instructions (Invitrogen). Quality and concentration of total RNA were assessed by capillary electrophoresis (Agilent Bioanalyzer 2,100, Agilent Technologies, Waldbronn, Germany).
cDNA macroarray analysis Paired (n=4) TG+/-and TG-/-cDNA expression arrays (Rat Atlas 1.2 II, Clontech, Palo Alto, CA, USA) containing 1,200 known rat genes were used with total RNA from the left ventricle of 20-weekold rats. Each sample was hybridised to a single cDNA array. 5 µg of each total RNA sample were converted into 32 P-dCTP-labelled cDNA using Superscript II RNase-reverse transcriptase (Invitrogen), an RNase H-MMLV mutant that appeared to produce more efficient and consistent labelling than the MMLV reverse transcriptase from Clontech kit. Hybridisation and washing of the macroarrays were carried out according to the Clontech technical manual in roller bottles. The paired membranes were exposed onto special crystal ray sensitive screens (Imaging Plate, FujiFilm, Kanagawa, Japan) for a sufficient period to visualise a maximal number of expressed genes. Screens were scanned using phosphorimager (FLA-8000, FujiFilm), and the images were analysed using ArrayGauge software (FujiFilm).
In order to explore the widest spectrum of expressed genes, several exposure times were required. However, at the shortest exposure time, housekeeping genes present in the membrane were not detected, while at a longer exposure time they appeared saturated. To overcome this problem for quantitation, we exposed the membrane with a scale of diluted 32 P labelled cDNA, which allowed us to normalise expression as cpm and to compare different experiments. Data were normalised and genes were selected for further analysis when measurements for paired (TG+/-and TG-/-) arrays fell within the linear range of calibration. For each experiment, the ratio of gene expression between the two paired samples was calculated. Genes for which the expression ratio was not reproducible across the four experiments (variation coefficient > 1) were excluded from further analysis.
Semi-quantitative reverse transcriptionpolymerase chain reaction (RT-PCR)
Total RNA for each sample was reverse transcribed to cDNA using random hexamers (pdN6-Amersham Pharmacia Biotec, Piscataway, NJ, USA) and Superscript II RNase-reverse transcriptase (Invitrogen), according to the manufacturer's instructions.The cDNA samples were subjected to PCR amplification using Platinum Taq DNA Polymerase (Invitrogen) with the reaction mixture recommended by the manufacturer's instructions. PCR was carried out using a PCR thermal cycler (Biometra ® ‚ T-Gradient thermoblock, Göttingen, Germany). The mRNA levels of APLP2, growth factor receptor-bound protein 14 (Grb14),APP and 18S were studied. Specific primers used, annealing temperature and the size of amplified products are shown in Table 1 . The number of cycles used to amplify each cDNA was set up to allow the PCR to proceed in a linear range.All samples for the paired comparisons were treated with the same RT mix and PCR mix. PCR amplification was conducted simultaneously for all paired samples at two different cycle numbers. Equal volumes of the amplified samples were loaded onto a 1.5% agarose gel stained with ethidium bromide. Bands were visualised by an ultraviolet transilluminator and photographed (Kodak Digital Science EDAS 120, Rochester, NY, USA).The density of each PCR band was measured and analysed by Kodak Digital Science 1D software. For each group (hypertensive and control rats), cDNA was measured at the same PCR cycle number and the amount of mRNA was expressed as the ratio to 18S rRNA product taken as internal control.
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Results
Selection of candidate genes
TG+/-20-week-old rats, compared with TG-/-controls, demonstrated a marked increase in SBP (191+9 mmHg vs. 144+5 mmHg, p<0.01) and significant LVH, expressed as left ventricular weight (LVw) to BW ratio (2.80+0.10 mg/g vs. 2.20+0.07 mg/g, p<0.01).
Out of 1,176 genes, 233 genes (19.8%) were measured in a reproducible way across the four experiments. Some known hypertrophic marker genes present on the membrane, such as α-actin and myosin heavy chain, were excluded from the analysis because their expression levels were too high in the array for correct quantitation. According to the results of SAM analysis, 22 genes (~10%) were differentially expressed with a fold change higher than 1.2 or lower than 0.8 in the left ventricle of 20-week-old TG+/-as compared with TG-/-rats ( Table 2) .We obtained three genes with higher expression and 19 genes with lower expression.
To corroborate the results of the macroarray analysis, we selected APLP2 and Grb14 to perform semi-quantitative RT-PCR in the same samples of 20-week-old TG+/-and TG-/-rats. The higher and lower expression levels of APLP2 and Grb14 respectively in the left ventricle of TG+/-were clearly confirmed by RT-PCR analysis. Left ventricle APLP2 mRNA level was significantly increased by about 70% (p<0.05) in TG+/-compared with TG-/-rats and Grb14 mRNA level was decreased by about 20% (p<0.05) (Figure 1 ). We selected APLP2 as a candidate gene for further analysis.
APLP2 during LVH development
We studied the expression of APLP2 in eight and 12-week-old TGR(mRen2)27 rats while LV mass index and blood pressure were increasing. APLP2 expression measured in eight and 12-week-old rats displayed the same difference, with higher levels by about 56% (p<0.01) and 64% (p<0.01) respectively, in TG+/-compared with TG-/-.
APLP2 and APP in genetically hypertensive rats
Phenotypic data of hypertensive 12-week-old rats and their control rats are shown in Table 3 . As expected, the hypertensive models demonstrated a marked increase in SBP and significant LVH compared with their respective controls.
APLP2 and APP were detected in the left ventricle of all hypertensive rats and their respective controls (Figure 2 ). In addition to the increase of APLP2 mRNA level, APP mRNA levels were increased by about 27% (p=0.055) in 12-week-old TG+/-rats, compared with their littermate control rats (Figure 2A) . No difference in the APLP2 mRNA level was observed between SHR and WKY rats. However, the APP mRNA level was significantly increased by about 37% (p<0.01) in SHR, compared with WKY control rats ( Figure 2B ). In LH compared with LL control rats, left ventricle APLP2 and APP mRNA levels were significantly decreased by about 12% (p<0.05) and 30% (p<0.05) respectively ( Figure 2C ).
Discussion
In the present study, we performed macroarray analysis of the left ventricle from TGR(mRen2)27 rats and their non-transgenic littermate controls. The 22 differentially expressed genes are essentially grouped into four subcategories: transcription factors (27%), metabolism (23%), cell signalling (18%) and extracellular matrix (13%). A. number = Accession number of sequences from Genbank; bp = base pair; F = forward primer; R = reverse primer; APLP2 = amyloid precursor like protein 2; Grb14 = growth factor receptor bound protein 14;APP = β-A4 amyloid precursor protein; 18S = ribosomal 18S subunit.
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C O P Y R I G H T J R A A S L I M I T E D R E P R O D U C T I O N P R O H I B I T E D
Three genes, biglycan, adenosine monophosphate (AMP)-activated protein kinase (AMPK)-β1 and APLP2 were found to be overexpressed in these rats (Table 2) . Biglycan is an extracellular matrix protein which binds collagen type I and may also bind transforming growth factor-β (TGF-β). 19, 20 It has been shown to be involved in the nephrotoxicity induced by cyclosporine A (CSA). 21 Interestingly, in rats, nephrotoxicity of CSA can be obtained only when animals are on a low-salt diet, known to induce kidney renin secretion. Biglycan overexpression has also been reported in pressure-overloaded rats with renal ischaemia, which induces renin secretion. 22 In the failing rat heart induced by ischaemia, biglycan is up-regulated in fibroblasts in an angiotensin II-AT 1 -receptor-dependent manner. 23 Since TGR(mRen2)27 rats develop renindependent hypertension, the overexpression of biglycan found in these rats is in accordance with these observations. In addition, two other genes of the extracellular matrix (apomucin and dentin sialophosphoprotein), not previously described in the heart, are found to be decreased in the TG+/-. Up-regulation of biglycan may thus contribute to the extracellular matrix remodelling induced by renin.
Among genes that are involved in metabolism, we found that the mRNA levels of AMPK-β1 were increased in TGR(mRen2)27 rats. AMPK is a heterotrimeric protein consisting of one catalytic α-subunit, as well as non-catalytic β and γ subunits and the heterotrimeric complex is necessary for significant kinase activity. Isoforms of all three subunits have been identified. AMPK regulates fatty acid oxidation and glucose uptake in the heart and skeletal muscle in response to altered energy supply and/or demand. 24, 25 AMPK activity (α1 and α2 subunits) was previously found to be increased in rat hearts with high renin pressure-overload hypertrophy, 26 as well as in the ischaemic heart 27 or during acute exercise in the heart. 28 It has been reported that different mutations in the AMPK γ2 subunit lead to the development of severe cardiac hypertrophy and Wolff-Parkinson-White syndrome. 29 Moreover, we showed that mRNA coding for enzymes involved in fatty acid beta-oxidation (mitochondrial 3-2 trans-enoyl-coA isomerase, mitochondrial long-chain 3-ketoacyl-coA thiolase, and mitochondrial acetoacetyl-coA thiolase) are decreased in TG+/-compared with TG-/-. All together, these data suggest that the renin-dependent cardiac hypertrophy of TGR(mRen2)27 rats is accompanied by an increased glucose uptake and a reduced beta-oxidation of lipids. In addition, we reported a decreased level of solute carrier PAPER Among the differentially expressed transcription factors, we note the decreased expression of clock genes, such as D-binding protein and DNAbinding protein N5. Recently, it has been shown that the expression of clock genes was decreased in the heart of two rat models developing cardiac hypertrophy with high or low renin. 31, 32 This indicates that pressure overload, and not renin, may be the trigger of this down-regulation, which may account for part of the loss of the circadian blood pressure rhythm observed in human hypertension. Interestingly, the decreased mRNA levels of nuclear factor I-C2 observed in this study may be part of the negative regulation of rat endogenous renin gene, since this family of nuclear factors has recently been shown to regulate renin expression. 33 In this work, macroarray data showed that APLP2 is overexpressed in TG+/-rats. However, no data on APLP2 in left ventricular hypertrophy or hypertension is available. We confirmed, by semiquantitative RT-PCR, that APLP2 was overexpressed in the left ventricle of 12 and 20-week-old TGR(mRen2)27 rats (Figures 1 and 2A ).
APLP2 appears to be involved in a number of activities, such as regulation of intracellular calcium, platelet aggregation, copper homeostasis and cell growth. 34 Single gene disruptions of APP, APLP1, or APLP2 can cause minor abnormalities and reduce body weight for APP -/-and APLP1 -/-knockout mice. Interestingly, mice with single knockout or double knockout (APP -/-and APLP1 -/-) are viable and fertile. However, 80% of the double knockout mice (APLP2 -/-/APP -/-or APLP2 -/-/ APLP1 -/-) die, with no histopathological anomalies, within the first week after birth. 35, 36 These observations demonstrate a key physiological role for APLP2 during development and indicate combined effects of APLP2 and each of the other family members (APP and APLP1). In addition, it has been demonstrated that the human APP, located on chromosome 21, belongs to a cluster of genes expressed in the cardiovascular system. 37 Recently, epidemiological studies showed a link between hypertension and AD, 38, 39 but the molecular mechanism is not known.The RAS and AD has been shown to be linked by the ACE genotype.The ACE Insertion/Deletion polymorphism has been investigated as potential genetic risk factor for AD. [40] [41] [42] Moreover, in this study we have shown by RT- Values are means + SEM. n = number of rats; SBP = systolic blood pressure; BW = Body weight; Heart w = Heart weight; LVw = Left ventricular weight; TG+/-= TGRm(Ren2)27 rats; TG-/-= non-transgenic TGR(mRen2)27 littermate rats; SHR = spontaneously hypertensive rats; WKY = Wistar-Kyoto rats; LH = Lyon hypertensive rats; LL = Lyon low blood pressure rats. * p<0.05 vs. control rats; ** p<0.01 vs. control rats; *** p<0.001 vs. control rats. PCR that mRNA levels of APP were also overexpressed in the left ventricle of TGR(mRen2)27 rats.To verify whether cardiac hypertrophy and/or hypertension were responsible for higher APLP2 and APP mRNA levels in the left ventricle of TG+/-, we compared their levels in two other genetically hypertensive rats (SHR and LH rats) with prominent cardiac hypertrophy and hypertension. The three hypertensive rat strains develop comparable LVH, although they show different blood pressure levels (Table 3) . Surprisingly, mRNA levels of APLP2 and APP were differently modified in the different hypertensive models (Figure 2) . Thus, as suggested by the developmental pattern of APP and APLP2 in TGR(mRen2)27 rats, neither elevated blood pressure nor LVH are responsible for the increased levels of APLP2 and APP in TGR(mRen2)27 rats.The main difference between the studied strains is that the monogenic TGR(mRen2)27 rat is characterised by pronounced activation of the RAS in several tissues, including the heart. [13] [14] [15] It has been demonstrated that overactive tissue RAS, and not pressure overload, may be primarily responsible for cardiac hypertrophy in this rat strain. 43 In SHR rats, the expression of angiotensinogen and renin was shown to be significantly higher than in WKY controls. 44, 45 The increased level of APP in SHR may be due to an overactive cardiac renin in this model. In contrast, LH rats have been defined as a low-renin hypertension model. 46 In conclusion, we identified new candidate genes related to extracellular matrix, metabolism and transcription factors in renin-dependent left ventricular hypertrophy. In addition, this work has shown, for the first time, that renin could regulate gene expression of the APP family in the heart. Further studies are needed to determine the mechanism by which renin can activate APLP2 and APP expression independently of blood pressure and whether such an effect is found in other tissues such as the central nervous system. 
